RankAlpha logo
Back to Rankings

BBLG

Bone BiologicsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Documented NB1 enrollment progress could strengthen the clinical case before the stated cash runway ends. The 10-Q describes a pilot evaluating fusion success, pain, function and adverse events, but supplies no efficacy result [#10-Q-2026-10-26].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Going-concern warning and funding need beyond the stated Q2 2027 runway [#10-Q-2026-10-26].
Momentum
82
Value
57
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.35 · Bull $0.80 · Bear $0.12Analysis 2026-10-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-27 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.20
Why
Momentum82 · Δ7d -
Value57 · Δ7d -0.1
Sentiment56 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Going-concern warning and funding need beyond the stated Q2 2027 runway [#10-Q-2026-10-26].
  • • NB1 enrollment and clinical outcomes remain unconfirmed; the latest filing gives no completed-enrollment count [#10-Q-2026-10-26].
  • • The company has no revenue from planned operations, used approximately $1.9 million in operating cash during the first nine months of 2026, and faces both going-concern and Nasdaq compliance risks.

Catalyst clock

2026-12-31

NB1 pilot enrollment progress

Lead driver: Value · See fundamentals
Momentum
82
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.6
Sentiment
56
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 81.9 / Value 56.7 / Sentiment 56.4

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-27. Scenario method

B+
Bull case
20%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.12
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$1.25M
Beta
0.75
Shares Out
2.76M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.31
Rev YoY
-
EPS YoY
-67.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.33M
Current Ratio
8.67
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data